Roundup, the most widely used herbicide on the planet, has been at the center of one of the largest mass tort litigations in American history after the World Health Organization’s International Agency for Research on Cancer classified its active ingredient, glyphosate, as “probably carcinogenic to humans” in 2015. Tens of thousands of plaintiffs who developed non-Hodgkin lymphoma and other cancers after prolonged Roundup exposure have filed lawsuits against Monsanto, now owned by Bayer AG, with individual settlement payouts historically ranging from roughly $10,000 to $165,000 depending on the severity of illness, strength of evidence, and tier placement within the settlement framework. Some trial verdicts have been dramatically higher, with juries awarding tens of millions and even billions of dollars before judicial reductions, though most claimants who settle outside of trial receive amounts within that broader range.
Bayer has committed approximately $10.9 billion to resolve Roundup litigation as of recent reports, making it one of the most expensive product liability settlements in corporate history. Despite this, the company has never admitted that Roundup causes cancer and continues to sell the product, although it announced plans to remove glyphosate from residential lawn and garden formulations in the U.S. market. This article breaks down what the WHO actually found, how the settlement tiers work, what real claimants have experienced, where the litigation stands now, and what you should know if you or a family member used Roundup regularly and later developed cancer.
Table of Contents
- Why Did the WHO Say Roundup Probably Causes Cancer, and What Does That Mean for Payouts?
- How the Settlement Tiers Actually Work and What Most People Receive
- What Happened in the Landmark Roundup Trials
- Should You File a Roundup Claim Now or Is It Too Late?
- The Regulatory Battle and Why the EPA and WHO Disagree
- What Bayer Has Done Since Acquiring Monsanto
- Where the Roundup Litigation Goes From Here
- Conclusion
- Frequently Asked Questions
Why Did the WHO Say Roundup Probably Causes Cancer, and What Does That Mean for Payouts?
In March 2015, the International Agency for Research on Cancer, a specialized arm of the World Health Organization, published a monograph classifying glyphosate as a Group 2A carcinogen, meaning “probably carcinogenic to humans.” This classification was based on a review of published scientific studies, including epidemiological research on agricultural workers showing associations between glyphosate exposure and non-Hodgkin lymphoma, as well as animal studies demonstrating tumor formation. The IARC panel concluded there was “limited evidence” of carcinogenicity in humans and “sufficient evidence” in experimental animals, which together warranted the Group 2A designation. This is the second-highest classification IARC uses, one step below Group 1, which includes substances like asbestos and tobacco smoke that are confirmed carcinogens. The IARC finding became the scientific backbone of the Roundup litigation. Plaintiffs’ attorneys used it to argue that Monsanto knew or should have known about cancer risks and failed to warn consumers. bayer and Monsanto have countered by pointing to regulatory agencies like the U.S. Environmental Protection Agency, which has maintained that glyphosate is “not likely to be carcinogenic to humans.” This regulatory split is important to understand because it explains why the litigation has been so contentious.
The EPA’s position does not invalidate the IARC finding. The two agencies used different methodologies and reviewed partially different data sets. IARC evaluates hazard, meaning whether a substance can cause cancer under any circumstance, while the EPA evaluates risk, meaning whether it is likely to cause cancer at real-world exposure levels. Both approaches have scientific merit, and both have been criticized. The practical consequence for claimants is that the IARC classification helped open the courthouse door but did not guarantee victory. Individual payouts have varied enormously depending on factors like how long someone used Roundup, their specific cancer diagnosis, their age, medical documentation, and whether internal Monsanto documents suggesting the company suppressed unfavorable research could be presented. The tiered settlement structure generally placed claimants into categories based on these factors, with those who had decades of heavy exposure and well-documented non-Hodgkin lymphoma diagnoses receiving higher amounts.
How the Settlement Tiers Actually Work and What Most People Receive
The Roundup settlement process has operated through a points-based system that evaluates each claim individually. Factors that increase a claimant’s point total, and therefore their potential payout, include the duration and frequency of Roundup use, the type and severity of cancer diagnosis, the strength of medical records linking exposure to illness, age at diagnosis, and the availability of corroborating evidence like purchase receipts or employer records. Claimants with the highest point totals, those with decades of occupational exposure as farmworkers or landscapers who developed aggressive forms of non-Hodgkin lymphoma, have historically fallen into the upper payment tiers. However, if you used Roundup casually in your backyard a few times per year and later developed cancer, your claim would likely fall into a lower tier or might not qualify at all. The litigation has primarily benefited individuals with significant, repeated exposure. Many claimants have reported frustration with the process, particularly around the time it takes to receive payment and the gap between headline-grabbing jury verdicts and actual settlement amounts.
The $289 million verdict for groundskeeper Dewayne Johnson in 2018, later reduced to $20.5 million, and the $2 billion verdict for Alva and Alberta Pilliod, later reduced to $86.7 million, created expectations that individual settlements could not realistically match. For the majority of claimants settling through the mass resolution process rather than going to trial, amounts in the range of $10,000 to $165,000 have been more typical, with many receiving amounts toward the lower end of that spectrum after attorney fees. It is also worth noting that some claims have been denied entirely. Not every person who used Roundup and developed cancer qualifies for compensation. The settlement requires a showing of meaningful exposure and a qualifying diagnosis, and claimants who cannot provide adequate documentation have been turned away. If you are considering filing a claim, the strength of your medical records and exposure history matters enormously.
What Happened in the Landmark Roundup Trials
Three early bellwether trials set the tone for the entire Roundup litigation and revealed internal Monsanto documents that proved damaging to the company’s public position. The first trial, Johnson v. Monsanto in 2018, involved a former school groundskeeper who applied Roundup regularly and was diagnosed with non-Hodgkin lymphoma. The jury awarded $289 million, which the trial judge later reduced to $78 million and an appellate court further reduced to approximately $20.5 million. Despite the reductions, the verdict was significant because it was the first time a jury concluded that Roundup was a substantial factor in causing cancer and that Monsanto had acted with malice or oppression by failing to warn users. The second trial, Hardeman v. Monsanto in 2019 in federal court, resulted in an $80 million verdict, later reduced to approximately $25 million.
The third, Pilliod v. Monsanto, produced the staggering $2 billion verdict that was subsequently reduced to $86.7 million. In each case, plaintiffs’ attorneys introduced internal Monsanto communications showing that the company had ghostwritten scientific papers, attempted to influence regulatory reviews, and attacked scientists whose research suggested glyphosate could be harmful. These documents, sometimes referred to as the “Monsanto Papers,” became publicly available and significantly shaped public perception of the company. These trials were not representative of what most claimants will experience. Going to trial is expensive, time-consuming, and risky. The vast majority of Roundup claims have been resolved or are being resolved through negotiated settlements rather than jury verdicts. But the trial results established that juries were willing to find Monsanto liable, which gave Bayer a strong incentive to settle rather than face thousands of individual trials.
Should You File a Roundup Claim Now or Is It Too Late?
Timing is a critical factor in Roundup litigation, and the window for filing new claims may be narrowing. Statutes of limitations vary by state, typically ranging from one to several years from the date of diagnosis or the date the claimant knew or should have known that Roundup was a potential cause of their cancer. Some states apply a “discovery rule” that starts the clock when the connection to Roundup becomes apparent rather than when the cancer is first diagnosed, but this is not universal. If you were diagnosed years ago and have not filed, you should consult an attorney in your state promptly because waiting could forfeit your right to compensation. There is a tradeoff between filing individually and joining a mass settlement. Individual lawsuits that go to trial can result in dramatically higher awards, as the bellwether cases demonstrated, but they also carry the risk of losing entirely, and they take years to resolve. Settling through the mass resolution framework is faster and more predictable, but amounts are generally much lower.
An attorney experienced in mass tort litigation can help assess which path makes more sense given the specifics of your case. Be wary of law firms that guarantee specific dollar amounts in advertising, as no honest attorney can promise a particular outcome. Bayer has also pursued a strategy of attempting to resolve future claims through various legal mechanisms, including a proposed class settlement that was rejected by a federal judge in 2021 and subsequent efforts to cap future liability. The legal landscape around future Roundup claims continues to evolve. As of recent reports, Bayer has indicated it may seek resolution through legislative or regulatory channels, and the U.S. Supreme Court has been asked to weigh in on whether federal pesticide labeling law preempts state failure-to-warn claims. A ruling in Bayer’s favor could significantly limit the ability of future plaintiffs to bring claims.
The Regulatory Battle and Why the EPA and WHO Disagree
The disagreement between the EPA and the WHO’s IARC on glyphosate’s cancer risk is not simply a matter of one agency being right and the other wrong. It reflects fundamentally different approaches to evaluating chemical safety. IARC’s classification process is hazard-based. It asks whether a substance is capable of causing cancer, considering the totality of published peer-reviewed research including studies on laboratory animals exposed to high doses. The EPA’s evaluation is risk-based, asking whether a substance is likely to cause cancer at the exposure levels people actually encounter during normal use. Both frameworks serve legitimate purposes, but they can produce different conclusions for the same chemical.
Critics of the EPA’s position have pointed to evidence that the agency’s review process was influenced by Monsanto. Internal company documents revealed in litigation showed that a senior EPA official had contact with Monsanto representatives during the review period and appeared to have helped the company manage the regulatory process. The EPA’s Office of Inspector General subsequently conducted a review of the agency’s handling of the glyphosate assessment. Critics of IARC’s position, meanwhile, have noted that the agency’s monograph program has been accused of selectively emphasizing studies that support a carcinogenicity finding and that the vast majority of regulatory agencies worldwide have sided with the EPA’s conclusion. For consumers, this regulatory ambiguity creates real confusion. If you are trying to decide whether to continue using glyphosate-based herbicides, the honest answer is that the science is genuinely contested at the institutional level. The precautionary approach would be to minimize exposure, particularly prolonged occupational exposure without protective equipment, which is the scenario most strongly linked to cancer in the epidemiological literature.
What Bayer Has Done Since Acquiring Monsanto
Bayer completed its $63 billion acquisition of Monsanto in June 2018, just weeks before the first Roundup trial verdict. The acquisition has widely been described as one of the worst corporate deals in modern history, with Bayer’s market capitalization dropping by more than the entire purchase price in the years following the deal as litigation costs mounted. The company has set aside approximately $10.9 billion for Roundup settlements and has faced intense pressure from shareholders, some of whom have voted against ratifying the management board’s actions.
In a notable concession, Bayer announced in 2021 that it would replace glyphosate with alternative active ingredients in its residential lawn and garden Roundup products sold in the United States, though it has continued to sell glyphosate-based Roundup for agricultural and professional use. The company framed this decision as a business move to reduce litigation exposure rather than an acknowledgment of health risks. For consumers, this means that newer Roundup formulations purchased for home use may no longer contain glyphosate, but professional and agricultural versions still do.
Where the Roundup Litigation Goes From Here
The future of Roundup litigation hinges on several unresolved legal and regulatory questions. The most consequential is whether the U.S. Supreme Court will take up the federal preemption question, which could determine whether state-law failure-to-warn claims against pesticide manufacturers are barred by the Federal Insecticide, Fungicide, and Rodenticide Act. If the Court rules that federal law preempts these claims, it could effectively end future Roundup litigation.
If it declines to intervene or rules against Bayer, thousands of additional claims could proceed. There is also the question of how long glyphosate itself will remain on the market. Several countries and municipalities have banned or restricted glyphosate use, and the European Union has gone through contentious renewal debates about whether to continue authorizing the chemical. Any significant change in the global regulatory consensus could affect both the trajectory of litigation and public health outcomes. For individuals who believe they were harmed by Roundup, the most important step remains consulting with a qualified attorney sooner rather than later, as legal deadlines do not wait for regulatory debates to conclude.
Conclusion
The Roundup litigation represents a collision between corporate science, independent research, regulatory politics, and the real suffering of people who developed cancer after years of using a product they were told was safe. The WHO’s classification of glyphosate as a probable carcinogen gave scientific credibility to claims that Monsanto had long tried to suppress, and the resulting lawsuits have produced both landmark jury verdicts and a massive settlement fund. Individual payouts have varied widely, with most claimants receiving between $10,000 and $165,000 through the settlement framework, though trial verdicts have at times reached into the tens of millions.
If you or a family member used Roundup extensively and were later diagnosed with non-Hodgkin lymphoma or another qualifying cancer, the time to evaluate your legal options is now, not after the regulatory and legal landscape shifts further. Document your exposure history, gather medical records, and speak with an attorney who handles mass tort cases. The legal process is slow and imperfect, but for thousands of claimants, it has provided at least some measure of accountability for a product whose risks were, at minimum, inadequately communicated to the people who trusted the label.
Frequently Asked Questions
Do I qualify for a Roundup settlement if I only used it a few times?
Qualification typically requires evidence of regular, sustained exposure to Roundup and a diagnosis of non-Hodgkin lymphoma or certain other cancers. Occasional use a handful of times may not meet the threshold, though each case is evaluated individually. The strength of your medical documentation and exposure history are the key factors.
Has Monsanto or Bayer admitted that Roundup causes cancer?
No. Bayer has consistently maintained that glyphosate-based herbicides are safe when used as directed and that the scientific evidence does not support a cancer link. The company’s settlement of claims has been framed as a business decision to resolve litigation, not an admission of liability.
How long does it take to receive a Roundup settlement payment?
Timelines have varied significantly. Some claimants have waited years after filing to receive payment, and the process involves claim evaluation, tier placement, and administrative review. Claimants who went to trial faced even longer timelines due to appeals. There is no standard timeline, and delays have been a common source of frustration.
Can I still file a new Roundup lawsuit?
It depends on your state’s statute of limitations and when you were diagnosed or became aware of the potential connection between Roundup and your illness. Some states have more generous filing windows than others. Consulting an attorney promptly is critical because delay could forfeit your right to claim compensation regardless of the merits.
Is Roundup still being sold with glyphosate?
As of recent reports, Bayer has replaced glyphosate with alternative ingredients in residential Roundup products sold in the U.S. However, glyphosate-based Roundup formulations remain available for agricultural and professional use. Consumers should check product labels carefully.